← 返回

浆母细胞性骨髓瘤的临床表现与治疗——一项多中心回顾性分析

英文原题:Clinical presentation and treatment of plasmablastic myeloma-a multicenter retrospective analysis.

查看英文原题

Clinical presentation and treatment of plasmablastic myeloma-a multicenter retrospective analysis.

PubMed 2026/04/20(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

PBM 发病率低,细胞增殖迅速,肿瘤负荷高,存在多种高危遗传学异常,病情进展快且预后差。PBM 常累及髓外部位。目前尚无针对 PBM 的标准治疗方案。CAR-T 疗法可能是一种新的选择。异基因造血干细胞移植也是探索的方向。

研究思路结论见上方概要

报告6例浆母细胞骨髓瘤(PBM)患者的临床表现、实验室检查、病理特征、诊疗经过及转归,并结合文献讨论PBM的临床特点及诊疗方法。

本研究为一项多中心病例系列研究,纳入6例患者的小样本(n = 6)。分析了患者的临床资料,如发病年龄、性别、病理类型、细胞遗传学特征、疾病分期、髓外病变等,并观察治疗后的疗效评价及结局。

6例PBM患者中,男2例、女4例,中位年龄为63(范围46-68)岁。3例为初诊,3例于复发时发现。5例Ki-67增殖指数高于65%。6例均出现髓外浸润。5例1q21扩增阳性。4例CD56阴性,1例部分阳性。5例患者经多个疗程化疗后死亡,1例仍在治疗中。

展开英文摘要原文

To report the clinical manifestations, laboratory tests, pathological features, diagnosis and treatment process and outcome of six patients with plasmablastic myeloma (PBM), and the clinical features and diagnosis and treatment methods of PBM were discussed in combination with literature.

The present study is a multicenter case series involving a small sample of six patients (n = 6). Clinical data of patients, such as age of onset, sex, pathological type, cytogenetic characteristics, disease stage, extramedullary disease were analyzed, and the efficacy evaluation and outcome after treatment were observed.

Among the 6 patients with PBM, 2 male and 4 female. The median age of the 6 patients was 63 (range 46-68) years. Three cases were newly diagnosed, three cases were found at the time of recurrence. The Ki-67 proliferation index of 5 cases was above 65%. Six cases all developed extramedullary infiltrates. Five cases were positive for 1q21 amplification. Four cases were negative for CD56 and one case was partially positive. Five patients died after multiple cycles of chemotherapy, and one patient is under treatment.

PBM has a low incidence, rapid cell proliferation, high tumor burden, multiple high-risk genetic abnormalities, rapid progression and poor prognosis. PBM frequently affects extramedullary sites. There is currently no standard treatment for PBM. CAR-T therapy may be a new option. Allogeneic hematopoietic stem cell transplantation is also the direction of exploration.

论文信息

作者
Lv Z、Guo X、Yin J、Lu P、Wu X、Xu X、Wang J、Wang Y
第一作者单位
Department of Hematology, Zibo Central Hospital, Zibo, 255000, China.China
通讯作者单位
Department of Hematology, Qingdao Hospital, Qingdao Municipal Hospital, University of Health and Rehabilitation Science, No.5 Donghai Middle Road, Shinan District, Qingdao, 266071, Shandong, China. zhongyp3352@126.com.China
期刊
Discover oncology2026 Apr 20
原文标识
PubMed 42010047 · DOI 10.1007/s12672-026-05071-4